Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 3 Interventional Results available

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

NCT01644331
View directory record Official record
Conditions
Heart Failure, Dyspnea
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Aurora, Colorado • Atlanta, Georgia • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Strawberries on Cardiovascular Disease Risk

NCT01989637
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Strawberry Meal, Control Meal
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 31, 2026, 10:51 PM EDT
Terminated Phase 2 Interventional Results available

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

NCT03137537
View directory record Official record
Conditions
Lymphoma, Autonomic Imbalance, Cancer Survivorship
Interventions
Ivabradine, Placebo Oral Tablet
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 3 Interventional Results available

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

NCT01150045
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
826
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

NCT03477175
View directory record Official record
Conditions
Solid Tumors
Interventions
E7080, Comparator Drug, Comparator Drug: Sorafenib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Torrance, California • Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of OV101 in Individuals With Angelman Syndrome (AS)

NCT04106557
View directory record Official record
Conditions
Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
Interventions
Gaboxadol, Placebo
Drug
Lead sponsor
Ovid Therapeutics Inc.
Industry
Eligibility
2 Years to 12 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 31, 2026, 10:51 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women

NCT01126801
View directory record Official record
Conditions
Menopausal Depression
Interventions
Estradiol, Placebo control
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Not applicable Interventional Results available

Androgen Effects in HIV-infected Women

NCT00095212
View directory record Official record
Conditions
HIV Infection
Interventions
1 Transdermal Testosterone (Patch), 2 Placebo Patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Oct 31, 2026, 10:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

NCT02170012
View directory record Official record
Conditions
Healthy Elderly
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 31, 2026, 10:51 PM EDT
Withdrawn Early Phase 1 Interventional

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712
View directory record Official record
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions
Terbinafine Tablets, Laboratory Testing
Drug · Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 31, 2026, 10:51 PM EDT
Recruiting Phase 2 Interventional

Limiting AAA With Metformin (LIMIT) Trial

NCT04500756
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 95 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 31, 2026, 10:51 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

NCT02760602
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
98
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Bone Response to Soy Isoflavones in Women

NCT00043745
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Soy isoflavones, Extract tablets
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Davis, California • Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 3 Interventional

Once Weekly Parathyroid Hormone for Osteoporosis

NCT00065637
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Teriparatide, Placebo teriparatide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 31, 2026, 10:51 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

NCT03912337
View directory record Official record
Conditions
Migraine
Interventions
Placebo, Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

NCT00348595
View directory record Official record
Conditions
Prostate Cancer
Interventions
Revlimid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 31, 2026, 10:51 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Zanzalintinib, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Marietta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

5-Alpha Reductase and Anabolic Effects of Testosterone

NCT00475501
View directory record Official record
Conditions
Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
Interventions
Testosterone Enanthate, Finasteride, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 2 Interventional

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

NCT04360681
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Lofexidine, Placebo oral tablet
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

2-HOBA: Multiple Dosing Study in Older Adults

NCT03556319
View directory record Official record
Conditions
Older Adults
Interventions
2-HOBA, Placebo
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 31, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

NCT02355028
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
Drug
Lead sponsor
Alcon, a Novartis Company
Industry
Eligibility
50 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 31, 2026, 10:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Diphenylcyclopropenone (DPCP) in Normals

NCT01452594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Diphenylcyclopropenone, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 31, 2026, 10:51 PM EDT